January 2011 Blog Posts (43)

New Therapeutic Approach Uses Adoptive Immunotherapy to Treat Various Cancers - Inducing Strong Responses in Metastatic Melanoma and Synovial Cell Sarcoma

Researchers have found that a novel form of personalized therapy that genetically engineers a patient’s own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers.

The technique, called adoptive immunotherapy, works with the body’s immune system to fight cancer. Immune cells, called T lymphocytes, are removed, modified,… Continue

Added by Peter Hofland, PhD on January 31, 2011 at 8:30pm — No Comments

Researchers Develop a Better and Safer Way to Make Induced Pluripotent Stem Cells

Researchers at Johns Hopkins have found a better way to create induced pluripotent stem (iPS) cells—adult cells reprogrammed with the properties of embryonic stem cells—from a small blood sample. This new method, described last week in Cell Research, avoids creating DNA changes that could lead to… Continue

Added by Peter Hofland, PhD on January 31, 2011 at 5:00pm — No Comments

Fast Track Designation for Carfilzomib, a Novel Treatment for Patients with Relapsed and Refractory Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has granted fast track designation for carfilzomib (Onyx Pharmaceuticals), a next generation proteasome inhibitor [1] for the potential treatment of patients with relapsed and refractory multiple myeloma. The Fast Track designation process was developed by the FDA to facilitate the development, and expedite the review of drugs to treat serious or life-threatening diseases and address… Continue

Added by Peter Hofland, PhD on January 31, 2011 at 4:30pm — No Comments

U.S. Food and Drug Administration Approves Rituximab For First-line Maintenance Use in Follicular Lymphoma

The U.S. Food and Drug Administration approved rituximab (Rituxan/MabThera, Roche/Genentech) as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with rituximab plus chemotherapy (induction treatment). This milestone follows the clearance of rituximab for this indication by the European Commission in October 2010.

Rituximab is a therapeutic antibody that binds to the CD20 antigen on the surface of normal… Continue

Added by Peter Hofland, PhD on January 31, 2011 at 1:00pm — No Comments

New Cancer-Targeting Investigational Nanoparticle Receives FDA IND Approval for First-In-Human Trial

Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for…


Added by Peter Hofland, PhD on January 31, 2011 at 12:30pm — No Comments

British Government Launches Cancer Campaign

The first ever government sponsored cancer awareness campaign to highlight the early signs and symptoms of bowel cancer is launched today, by the United Kingdom’s Health Minister Paul Burstow. The ‘Be Clear on Cancer’ campaign will initially be piloted in two regions and if successful will be rolled out across the country. Improving cancer outcomes is a Government priority and the earlier cancer…


Added by Peter Hofland, PhD on January 31, 2011 at 9:00am — No Comments

New National Conference on Breast Cancer Highlights Emerging Surgical Techniques Focussing on Medical and Cosmetic Outcomes

A new national conference on breast cancer hosted and sponsored by Georgetown University Hospital in Washington, DC, will spotlight important developments in breast cancer care including surgical techniques such as nipple-sparing mastectomies with breast reconstruction that not only remove the cancer but also allow women to have natural, healthy breasts.

The Georgetown University…


Added by Peter Hofland, PhD on January 31, 2011 at 6:00am — No Comments

Sanofi-Aventis In-licenses Therapeutic Antibody for the Treatment of Solid Cancers From Oxford BioTherapeutics’ – Other companies also involved in the development of ADCs

Earlier this month French pharmaceutical giant Sanofi-aventis acquired an exclusive world-wide license to one of Oxford BioTherapeutics’ internal preclinical antibody programs. Sanofi-aventis intends to use the licensed antibody, which is directed against a novel, proprietary target identified by Oxford BioTherapeutics’, to develop, manufacture and commercialize antibody-drug conjugate (also called immuno-conjugate)…


Added by Peter Hofland, PhD on January 28, 2011 at 9:30pm — No Comments

Study Show Progression-free Survival Benefit of First-line Erlotinib in Advanced Lung Cancer with EGFR Mutations

An independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study met its primary endpoint. At a planned interim analysis it was shown that compared to platinum-based chemotherapy erlotinib (Tarceva®, Roche/Genentech/OSI Oncology) significantly extended the time people with newly diagnosed advanced non small cell lung cancer (NSCLC) with EGFR (epidermal growth factor… Continue

Added by Peter Hofland, PhD on January 28, 2011 at 11:30am — No Comments

Radiotherapy Helps Cure 40% of Cancer Patients: Saving Thousands of Lives

Today sees the launch of The Year of Radiotherapy, an initiative to raise awareness of radiotherapy as a cost-effective, cutting-edge treatment that can help cure cancer. According to figures published by Cancer Research UK, only 1 in 10 people know that radiotherapy helps cure 40% of cancer patients. A report from the national charity estimates that only 38% of cancer patients in England are getting…


Added by Peter Hofland, PhD on January 28, 2011 at 4:30am — No Comments

Iniparib (BSI-201) Does Not Meet Pre-specified Criteria in Metastatic Triple-Negative Breast Cancer Phase III Study

Results from a randomized Phase III trial evaluating iniparip (BSI-201) in patients with metastatic triple-negative breast cancer (mTNBC) show that the trial did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and progression-free survival.

When women are diagnosed with breast cancer, their tumors are routinely tested for the presence of estrogen and progesterone receptors and for the over-expression of…


Added by Peter Hofland, PhD on January 27, 2011 at 2:00pm — No Comments

'Cancer in Africa: the Runaway Train' - Will Launch on World Cancer Day 2011

Cancer. It is expected that by 2020 there will be 16 million new cases of cancer each year. Seventy percent of these cases will be in developing countries. African countries are the least able of all developing countries to cope, having few cancer care services. Most Africans have no access to cancer screening, early diagnosis, treatment or palliative care. Consequently a diagnosis of cancer leads, in most cases, to a painful and distressing death.…


Added by Peter Hofland, PhD on January 27, 2011 at 5:00am — No Comments

Possible Link Found Between Breast Implants and Anaplastic Large Cell Lymphoma

The U.S. Food and Drug Administration today announced a possible association between saline and silicone gel-filled breast implants and anaplastic large cell lymphoma (ALCL), a very rare type of cancer. Data reviewed by the FDA suggest that patients with breast implants may have a very small but significant risk of ALCL in the scar capsule adjacent to the implant.

The FDA is requesting that health care professionals report any confirmed cases of ALCL in…


Added by Peter Hofland, PhD on January 26, 2011 at 3:30pm — No Comments

Frequent and Severe Hot Flashes and Other Menopause Symptoms Associated with a Significant Reduction in Breast Cancer Risk

Women who have experienced hot flashes and other symptoms of menopause may have a 50% lower risk of developing the most common forms of breast cancer than postmenopausal women who have never had such symptoms, according to a recent study by researchers at Fred Hutchinson Cancer Research Center. The results of the first study to examine the relationship between menopausal symptoms and breast cancer risk are available online ahead…


Added by Peter Hofland, PhD on January 25, 2011 at 5:00pm — No Comments

Notch1 Signaling Study Raises Safety Concerns About Experimental Cancer Approach

A study by researchers at the Washington University School of Medicine and the Siteman Cancer Center has raised safety concerns about an investigational approach to treating cancer. The strategy takes aim at a key signaling pathway, called Notch, involved in forming new blood vessels that feed tumor growth.

When researchers targeted the Notch1… Continue

Added by Peter Hofland, PhD on January 25, 2011 at 4:30pm — No Comments

New Publication - Practical Radiation Oncology - Will Serve as Worldwide Forum for Radiation Oncologists

Earlier this week Dutch scientific and medical publisher Elsevier, on behalf of the American Society for Radiation Oncology(ASTRO), anounced the publication of the first issue of Practical Radiation Oncology (PRO).

ASTRO is the largest radiation oncology society in the world, with more than 10,000 members who specialize in treating patients with…


Added by Peter Hofland, PhD on January 25, 2011 at 5:00am — No Comments

Guideline Helps Doctor and Patient with Candid Discussion About End-of-Life Cancer Care

In a new policy statement released earlier today, the American Society of Clinical Oncology (ASCO) calls on physicians, medical schools, insurers, and others to help improve quality of life for people with advanced cancer. In the guidline ASCO recommends steps to ensure that physicians initiate candid discussions about the full range of palliative care…


Added by Peter Hofland, PhD on January 24, 2011 at 9:30pm — No Comments

Promising Clinical Trial of DCVax® for Brain Cancer Resumes Enrollment of New Patients

A Phase II trial with an investigational therapy called DCVax® (Northwest Biotherapeutics), a personalized vaccine that takes a patient’s immune cells and the biomarkers from that patient’s tumor tissue to mobilize the full immune system response to recognize and kill the tumor cells, resumes enrollment.

The purpose of the ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical…


Added by Peter Hofland, PhD on January 24, 2011 at 4:30am — No Comments

Colorectal Cancer Patients at Risk for Recurrence May be Indentified by Gene Signature

Molecular staging or genomic profiling holds promise in predicting the long-term outcome of an individual patient based on the gene expression profile of their cancer at diagnosis. Researchers have shown that a gene signature test – called ColoPrint – that analyzes the expression of 18 genes can identify the risk of recurrence in colorectal cancer patients with localized, stage II disease.

Such a gene signature test could have important implications for…


Added by Peter Hofland, PhD on January 22, 2011 at 4:30pm — No Comments

Positron Emission Tomography (PET) Detected Responses to Chemotherapy Help to Determine Prognosis in Rare Esophageal Cancer

A prospective study, MUNICON II, has shown that detecting early metabolic response to chemotherapy by positron emission tomography (PET) imaging prior to surgery is useful in determining a patient’s prognosis for locally advanced adenocarcinoma of the esophagogastric junction. Researchers also found that those who did not respond to chemotherapy did not benefit from additional radiation. The study results were presented during the eighth annual Gastrointestinal Cancers Symposium,…


Added by Peter Hofland, PhD on January 20, 2011 at 6:30pm — No Comments

Monthly Archives














Register for free to view all the Onco'Zine - The International Oncology Network content:


Onco'Zine is present here

Bookmark / Share



© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+